萊茵生物(002166.SZ)：孫公司擬為A公司提供工業大麻提取代工
格隆匯3月21日丨萊茵生物(002166.SZ)公吿稱，公司經公司第五屆董事會第十五次會議、2019年第2次臨時股東大會審議通過，在美國投資建設“工業大麻提取及應用工程建設項目”。2021年10月，公司工業大麻提取工廠建成投產試運行。
工業大麻建設項目試運行以來，由於新冠疫情導致國際物流運輸及人員往來方面受到限制，目前公司正積極克服疫情影響，大力開展技術人員委派和設備及工藝調試工作，加快推進項目的順利量產。公司預計該項目將於2022年6月30日前達成正式量產。
近日，公司孫公司HempRise,LLC(簡稱“Hemprise”)與美國一家工業大麻產品提供商(簡稱“A公司”)簽訂了一份《受託加工意向協議》，協議主要內容如下：
(1)合作意向：計劃2022年8月至12月期間，A公司將委託Hemprise加工50萬鎊(1磅=0.454kg，約227噸)的工業大麻原料，具體的協議執行開始日期有可能早於8月，視Hemprise工廠正式量產時點而定；Hemprise根據其規格要求將原料加工成高純度CBD晶體或粉末提供給A公司。原料和產品的運輸費用均由A公司負責。
(2)具體內容：A公司提供的原料將符合Hemprise的要求(CBD含量＞6%，THC含量＜0.3%，水分含量＜10%等)，另外雙方就每月提供的原料數量、交付產品要求、加工費用單價、運費、產品包裝形式等進行了約定。
(3)交易金額：根據本協議約定的每磅加工費單價區間，公司初步估計本協議的加工費金額將超過255萬美元，最高將不超過570萬美元。具體交易金額將根據原料含量、產品純度、實際回收率等因素確定。(4)協議經雙方簽字(含電子郵件簽名)後生效。
根據資料顯示，A公司是全球工業大麻市場的一家主流企業，專注於為醫療保健部門提供大麻衍生物和大麻二酚產品。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
